Top

Published in:

01-04-2007 | Original Article

Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient

Authors: Rikke Bæk Sørensen, Sine Reker Hadrup, Tania Køllgaard, Inge Marie Svane, Per thor Straten, Mads Hald Andersen

Published in: Cancer Immunology, Immunotherapy | Issue 4/2007

Abstract

Based on the detection of spontaneous immune responses in cancer patients with cancer of different origin, Bcl-X(L) was recently described as a highly interesting tumor antigen recognized by CD8 positive cytotoxic T lymphocytes. To further characterize Bcl-X(L) as a tumor antigen we isolated and expanded Bcl-X(L) specific T cells from the peripheral blood of a breast cancer patient hosting a strong Bcl-X(L) specific T cell response. We describe that HLA-A2 restricted Bcl-X(L) specific T cell clones very efficiently lyse peptide pulsed T2 cells. Furthermore, tumor cell lines of different origin, i.e., breast cancer, colon cancer, and melanoma, are efficiently lysed in an HLA-dependent manner. Finally, ex vivo-isolated leukemia cells, but not non-malignant B and T cells are killed by Bcl-X(L) specific T cells. Our data underline Bcl-X(L) as an universal tumor antigen widely applicable in specific anticancer immunotherapy.

Andersen MH, Bonfill JE, Neisig A, Arsequell G, ndergaard I, Neefjes J, Zeuthen J, Elliott T, Haurum JS (1999) Phosphorylated peptides can be transported by tap molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol 163:3812PubMed

Andersen MH, Pedersen LO, Becker JC, thor Straten P (2001) Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein survivin in cancer patients. Cancer Res 61:869PubMed

Andersen MH, Reker S, Kvistborg P, Becker JC, thor Straten P (2005) Spontaneous immunity against Bcl-X(L) in cancer patients. J Immunol 175:2709PubMed

Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB (1993) Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597PubMedCrossRef

Cameron RB, Spiess PJ, Rosenberg SA (1990) Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med 171:249PubMedCrossRef

Fry TJ, Mackall CL (2001) Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol 22:564PubMedCrossRef

Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071PubMed

Kirkin AF, Reichert Petersen T, Olsen AC, Li L, thor Straten P, Zeuthen J (1995) Generation of human-melanoma specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol Immunother 41:71PubMed

Levings MK, Sangregorio R, Roncarolo MG (2001) Human cd25( + )cd4( + ) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 193:1295PubMedCrossRef

10.

Nakagawara A (1998) Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum Cell 11:115PubMed

11.

Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, Isaacs JD, Lechler RI (2001) Human CD4( + )CD25( + ) cells: a naturally occurring population of regulatory T cells. Blood 98:2736PubMedCrossRef

12.

Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, Grunebach F, Brossart P (2003) Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102:571PubMedCrossRef

13.

Shangary S, Johnson DE (2003) Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 17:1470PubMedCrossRef

14.

Wacheck V, Selzer E, Gunsberg P, Lucas T, Meyer H. Thallinger C, Monia BP, Jansen B (2003) Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells. Br J Cancer 89:1352PubMedCrossRef

15.

Wang S, Yang D, Lippman ME (2003) Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 30:133PubMedCrossRef

Title: Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient
Authors: Rikke Bæk Sørensen
Sine Reker Hadrup
Tania Køllgaard
Inge Marie Svane
Per thor Straten
Mads Hald Andersen
Publication date: 01-04-2007
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 4/2007
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-006-0200-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2007

Regulation of galectin-1 expression by transforming growth factor β1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape

International Meeting “Immunotherapy of Cancer: Challenges and Needs”

Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients

Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion

CD1 expression and CD1-restricted T cell activity in normal and tumour-bearing human liver

Synthesis of glycosylated human tumor necrosis factor α coupled with N-acetylneuraminic acid

Keynote webinar | Spotlight on antibody–drug conjugates in cancer